Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EBITDA (2019 - 2025)

Historic EBITDA for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to -$7.1 million.

  • Biodesix's EBITDA rose 1792.57% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.6 million, marking a year-over-year increase of 623.29%. This contributed to the annual value of -$34.5 million for FY2024, which is 1655.46% up from last year.
  • Biodesix's EBITDA amounted to -$7.1 million in Q3 2025, which was up 1792.57% from -$9.7 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's EBITDA ranged from a high of -$5.6 million in Q1 2021 and a low of -$16.4 million during Q1 2023
  • Over the past 5 years, Biodesix's median EBITDA value was -$10.6 million (recorded in 2021), while the average stood at -$10.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 34021.86% in 2021, then soared by 5054.0% in 2023.
  • Quarter analysis of 5 years shows Biodesix's EBITDA stood at -$11.7 million in 2021, then dropped by 18.93% to -$13.9 million in 2022, then surged by 50.54% to -$6.9 million in 2023, then rose by 3.22% to -$6.6 million in 2024, then dropped by 6.05% to -$7.1 million in 2025.
  • Its last three reported values are -$7.1 million in Q3 2025, -$9.7 million for Q2 2025, and -$9.1 million during Q1 2025.